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Risk profile scores (RPS) derived from genome-wide associa-
tion studies (GWAS) explain a considerable amount of sus-
ceptibility for schizophrenia (SCZ). However, little is known 
about how common genetic risk factors for SCZ influence 
the structure and function of the human brain, largely due to 
the constraints of imaging sample sizes. In the current study, 
we use a novel recall-by-genotype (RbG) methodological 
approach, where we sample young adults from a population 
cohort (Avon Longitudinal Study of Parents and Children: 
N genotyped  =  8365) based on their SCZ-RPS. We com-
pared 197 healthy individuals at extremes of low (N = 99) or 
high (N  =  98) SCZ-RPS with behavioral tests, and struc-
tural and functional magnetic resonance imaging (fMRI). 
We first provide methodological details that will inform the 
design of future RbG studies for common SCZ genetic risk. 
We further provide an between group analysis of the RbG 
individuals (low vs high SCZ-RPS) who underwent structural 
neuroimaging data (T1—weighted scans) and fMRI data 
during a reversal learning task. While we found little evi-
dence for morphometric differences between the low and high 
SCZ-RPS groups, we observed an impact of SCZ-RPS on 
blood oxygen level-dependent (BOLD) signal during reward 
processing in the ventral striatum (PFWE-VS-CORRECTED = .037), 
a previously investigated broader reward-related network 
(PFWE-ROIS-CORRECTED  =  .008), and across the whole brain 
(PFWE-WHOLE-BRAIN-CORRECTED  =  .013). We also describe the 
study strategy and discuss specific challenges of RbG for 
SCZ risk (such as SCZ-RPS related homoscedasticity). This 
study will help to elucidate the behavioral and imaging pheno-
types that are associated with SCZ genetic risk.
Key words:  schizophrenia/polygenic/recall-by-genotype/ 
reward processing/imaging genetics
Introduction
Schizophrenia (SCZ) has a broad genetic architecture, 
characterized by thousands of common genetic vari-
ants (single nucleotide polymorphisms; SNPs)1 and rare 
pathogenic copy number variations (CNVs).2 These loci 
demonstrate biological convergence on central nervous 
system pathways such as voltage-gated calcium channel 
signaling, fragile X mental retardation protein (FMRP) 
gene targets, and excitatory/inhibitory synaptic neuro-
transmission.3 SCZ polygenicity also confers susceptibil-
ity to other psychiatric disorders, suggesting a shared, 
common etiology.4 While the cumulative (polygenic) 
effects of currently identified risk alleles explain approxi-
mately 7% of SCZ liability, these risk profile scores (RPS) 
do not yet offer predictive utility.1 However, SCZ-RPS 
are useful in identifying causal antecedents that predict 
disease risk such as reduced cognitive ability,5 increased 
substance use6,7 and higher incidence for specific SCZ 
symptom dimensions.8 SCZ loci also show genetic over-
lap with a number of polygenic, heritable traits, includ-
ing personality, education and socioeconomic status.9–12 
SCZ-RPS has also been combined with neuroimaging 
measures to identify disturbances in brain structure and 
function that reflect mechanisms of SCZ disease patho-
genesis. These SCZ-RPS neuroimaging studies broadly 
suggest that the subcortical structural abnormalities 
observed in SCZ have little/no overlap with SCZ genetic 
etiology. However, behavioral and neural measures of 
cognition (eg, using functional magnetic resonance imag-
ing [fMRI]) may reflect disease susceptibility.13–17 These 
imaging SCZ-RPS studies support theories that cogni-
tive dysfunction is a risk factor for SCZ, while at least 
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some of the alterations in subcortical brain volumes may 
be downstream effects of disease processes (reverse cau-
sation).18,19 Such genetic neuroimaging studies provide 
insight into the neurobiological mechanisms of SCZ, but 
are limited by sample size and heterogeneity.20
We first describe the recall-by-genotype (RbG) 
approach for neuroimaging SCZ-RPS. By assaying SCZ-
RPS in a large, genotyped population, we are able to 
recruit a subset of individuals from the general popula-
tion who have either extremely low or high SCZ-RPS, 
enriching the sample for a large amount of variation in 
SCZ-RPS, while minimizing problems with confound-
ing and reverse causation that exist in samples of clini-
cally ascertained individuals.21 As there is considerably 
increased SCZ risk (as indexed by odds ratio [OR]) in 
SCZ-RPS between the 1st and 10th decile,1 the current 
study offers considerably more power than an opportu-
nistic sample (see Materials and Methods section).
In the current study, we assay neuroimaging pheno-
types robustly linked to SCZ. There is reliable evidence 
that subcortical volume,22 cortical thickness/surface area 
are reduced in SCZ.23 There is also converging evidence 
that fMRI phenotypes, such as blood oxygen level-depen-
dent (BOLD) signal relating to rewarding stimuli in the 
ventral striatum (VS) is altered in SCZ.24 However, it is 
largely unknown whether these alterations are linked to 
the common genetic risk for SCZ. Studies further suggest 
potential alterations in morphometric25–27 and VS-BOLD 
measures28–31 in relatives/offspring of patients with SCZ, 
suggesting putative familial effects. However, these stud-
ies cannot infer that common SCZ risk alleles explain 
these putative observations. Preliminary studies using 
SCZ-RPS suggest that the morphometric alterations 
observed in SCZ are largely not related to an individual’s 
burden of common SCZ risk alleles.13,32,33 In contrast, 
our preliminary work suggests common SCZ-RPS may 
explain some of the variance in the VS-BOLD response 
(as indexed by VS-BOLD).14,34 Together, these observa-
tions suggest that the SCZ-RPS is related to VS-BOLD 
but not morphometric measures such as subcortical vol-
ume. In the current study, we therefore aim to confirm 
the hypothesis that SCZ-RPS may influence fMRI phe-
notypes (such as VS-BOLD and across a wider network 
of previously investigated reward-related ROIs14), while 
morphometric measures (such as subcortical volumes) 
will remain largely unaffected.
Materials and Methods
ALSPAC Participants
The broader cohort sample from which we selected 
individuals consisted of young individuals recruited 
via the ALSPAC cohort. This broader cohort con-
sisted of 14 062 children born to women residing in the 
former Avon Health Authority area with an expected 
delivery date from April 1, 1991 to December 31, 1992 
(http://www.bristol.ac.uk/alspac/; available at http://
www.bristol.ac.uk/alspac/researchers/access/). Data were 
collected periodically from September 6, 1990, and col-
lection is ongoing. Ethical approval for the study was 
obtained from the ALSPAC Law and Ethics Committee 
and the local research ethics committees (listed at http://
www.bristol.ac.uk/alspac/researchers/research-ethics/).
ALSPAC Participant Genotyping
All individuals recruited via the ALSPAC sample were 
genotyped using the Illumina HumanHap550 quad chip 
genotyping platforms by 23andme subcontracting the 
Wellcome Trust Sanger Institute, Cambridge, UK and 
the Laboratory Corporation of America, Burlington, 
NC. The raw genome-wide data were subjected to stand-
ard quality control methods. Briefly, individuals were 
excluded on the basis of gender mismatches; minimal or 
excessive heterozygosity; disproportionate levels of indi-
vidual missingness (>3%) and insufficient sample replica-
tion (IBD < 0.8). Population stratification was assessed 
by multidimensional scaling analysis and compared with 
Hapmap II (release 22)  European descent (CEU), Han 
Chinese, Japanese, and Yoruba reference populations; all 
individuals with non-European ancestry were removed. 
SNPs with a minor allele frequency of <1%, a call rate of 
<95% or evidence for violations of Hardy-Weinberg equi-
librium (P < 5E-7) were removed. Cryptic relatedness was 
measured/excluded as proportion of identity by descent 
(IBD > 0.1). Related subjects that passed all other qual-
ity control thresholds were retained during subsequent 
phasing and imputation. Nine thousand one hundred 
fifteen subjects and 500 527 SNPs passed these quality 
control filters. We combined 477 482 SNP genotypes in 
common between the sample of mothers and sample of 
children. We removed SNPs with genotype missingness 
above 1% due to poor quality (11 396 SNPs removed) and 
removed a further 321 subjects due to potential ID mis-
matches, resulting in a data set containing 465 740 SNPs. 
We estimated haplotypes using ShapeIT (v2.r644) which 
utilizes relatedness during phasing. We obtained a phased 
version of the 1000 genomes reference panel (phase 1, 
version 3)  from the Impute2 reference data repository 
(phased using ShapeIt v2.r644, haplotype release date 
Dec 2013). Imputation of the target data was performed 
using Impute V2.2.2 against the reference panel (all pol-
ymorphic SNPs excluding singletons), using all 2186 
reference haplotypes (including non-Europeans). After 
quality control, a total of 8365 individuals were geno-
typed and underwent SCZ-RPS calculations.
ALSPAC Participant SCZ-RPS Creation
Construction of the SCZ-RPS follows the meth-
ods described by the International Schizophrenia 
Consortium,35 using results from the Psychiatric 
Genomics Consortium (PGC) SCZ genome-wide 
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association studies (GWAS).1 Polygenic scores were cal-
culated for each ALSPAC individual using the “score” 
command in PLINK (version 1.07).36 Individual SCZ-
RPS were created by summing the number of risk alleles 
present for each SNP (0, 1, or 2) weighted by the loga-
rithm of each SNP’s OR for SCZ from the PGC summary 
statistics for each individual. Our SCZ-RPS–based RbG 
was solely based upon a RPS generated from SNPs with 
a GWAS training-set P ≤. 05 threshold, approximately 
5% of all imputed SNPs. This threshold was specifically 
chosen as it captures the most SCZ liability (most vari-
ance explained) in the primary RPS analysis using train-
ing data/summary statistics derived from the largest SCZ 
GWAS of 34 241 SCZ cases and 45 604 controls.1
SCZ-RPS Stratification and Cardiff Subsample
From the 8365 individuals who were considered for SCZ-
RPS calculation, a total of 197 individuals (99 with low 
SCZ-RPS, 98 with high SCZ-RPS) participated in a 
battery of psychometric/neuroimaging paradigms, pre-
viously linked to the etiology of SCZ. A  further 104 
individuals declined our invitation (by written reply) to 
participate in the study (low SCZ-RPS [n  =  40]; high 
SCZ-RPS [n = 64]), conforming to prior observations that 
SCZ-RPS is related to nonparticipation.37 Researchers 
were blind to which tail of the SCZ-RPS distribution 
each individual was selected from during the data col-
lection and processing. All participants provided written 
informed consent. The SCZ-RPS groups were matched 
for gender (low SCZ-RPS: 52 female, 47 male; high SCZ-
RPS: 52 female, 46 male).
A Priori Power Analysis
Using the RbG approach, we estimated we had >80% 
power to detect an relatively small effect (R2 > .03), at a 
conservative alpha level (alpha > 0.001); see supplementary 
methods S1 and supplementary figure S1 for further details.
Psychotic Experiences and Cognition
The semi-structured Psychosis-Like Symptom Interview 
was used to assess psychotic experiences (hallucinations, 
delusions, or experiences of thought interference) at 
18 years of age.38 Individuals were deemed to have a psy-
chotic experience if  rated as having 1 or more suspected 
and/or definite psychotic experiences at 18 years of age 
(pliks18). Individuals were administered the short form 
Wechsler Intelligence Scale for Children (WISC-III) at 
8 years of age.39 Scores for verbal, performance, and total 
IQ were taken forward for SCZ-RPS regression analysis.
Statistical Analysis
Associations between SCZ-RPS groups and psychotic 
experiences were explored using Firth’s Bias-Reduced 
Logistic Regression via the logistf  package in R.40 This 
approach computes confidence intervals computed by 
penalized profile likelihood to control for rare events. 
For WISC-III, Verbal, Performance, and Total IQ from 
the WISC were regressed against SCZ-RPS in a series of 
linear models. Gender was added into each model as a 
regressor in all cases.
Structural Imaging Preprocessing and Analysis
Structural brain scans were acquired for each individ-
ual using a 3T GT HDx system at Cardiff  University 
Brain Research Imaging Centre (CUBRIC), School 
of Psychology, Cardiff  University. High-resolution 
3-dimensional T1-weighted images were acquired using 
a 3-dimensional fast spoiled gradient echo sequence 
(FSPGR) with contiguous sagittal slices of 1 mm thick-
ness (TR 7.9 s, TE 3.0 ms, TI 450 ms, flip angle 20°, FOV 
256 mm × 256 mm × 176 mm to yield 1 mm isotropic 
voxel resolution images. Cortical and subcortical seg-
mentations for each subject were estimated with well-val-
idated segmentation software FreeSurfer version 6.0.41 In 
alignment with ENIGMA analysis strategies in SCZ and 
genomics,13,22,23 we explored (1) subcortical volume (mm3) 
(2) cortical (a) thickness (mm) and (b) surface area (mm2). 
Segmentations of 68 (34 left/right) cortical gray matter 
regions were created based on the Desikan–Killiany atlas 
and 7 subcortical regions (as well as the hemispheric total 
intracranial volume, average cortical thickness, and sur-
face area). Segmented subcortical and cortical regions 
were visually inspected and statistically evaluated for out-
liers following standardized ENIGMA protocols (http://
enigma.ini.usc.edu/protocols/imaging-protocols). For 
the statistical analysis, we averaged each segmentation/
parcellation across hemispheres. Each ROI was regressed 
against SCZ-RPS group (low/high) with gender & ICV 
added as covariates. Age was not included as a covariate 
as all participants were born in the same year.
Functional Imaging Acquisition and Preprocessing
Gradient echoplanar imaging data were acquired for 
each subject on the same 3T GT HDx system with an 
8-channel receiver at CUBRIC (Cardiff  University 
Brain Research Imaging Centre), School of Psychology, 
Cardiff  University (parameters: 35 slices, slice thick-
ness; 3 mm/1 mm gap, acquisition matrix; 64 × 64; FOV; 
220  mm, TR 2000  ms, TE 35  ms, flip angle 90°, accel-
eration [ASSET] factor; 2). All functional images were 
first motion scrubbed, where TRs with a frame wise 
displacement >0.9 were removed, as previously recom-
mended.42 Image processing and statistical analyses were 
conducted using statistical parametric mapping methods 
as implemented in FMRI Expert Analysis Tool (FEAT, 
Version 5.98, part of FMRIB’s Software Library, www.
fmrib.ox.ac.uk/fsl). The following prestatistics process-
ing was applied; motion correction using MCFLIRT43; 
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slice-timing correction using Fourier-space time-series 
phase-shifting; nonbrain removal using BET (Brain 
Extraction Tool)44 spatial smoothing using a Gaussian 
kernel of FWHM 5 mm; grand-mean intensity normali-
zation of the entire 4D data set by a single multiplicative 
factor; high-pass temporal filtering (Gaussian-weighted 
least-squares straight line fitting, with sigma  =  50.0  s). 
Registration to high resolution structural (single subject 
general linear model [GLM]) and standard space (group-
level GLM) images was carried out using FLIRT.43 Time-
series analysis was carried out using FMRIB’s Improved 
Linear Model (FILM) with local autocorrelation correc-
tion.45 To further correct for any potential movement con-
founds, motion regressors were estimated via MCFLIRT 
and scrubbed TRs were added as covariates of no inter-
est to each individual design matrix. After quality con-
trol procedures, 183 individuals out of the 197 (89 low 
SCZ-RPS and 94 high SCZ-RPS) where included in the 
reversal learning analysis.
Functional Imaging Paradigm: Reversal Learning
Participants learned to choose 1 of 2 simultaneously pre-
sented colors (“blue” and “green”) by receiving monetary 
reward for correct choices and monetary punishment 
for wrong choices (eg, +1 pence [p] for “blue” and −1p 
for “green”). After 7–11 trials, reward/punishment con-
tingencies were reversed so that the previously rewarded 
color was now punished and vice versa. Participants were 
instructed to maximize their earnings during the learn-
ing session, which consisted of 12 reversal episodes in 
total (108 choice trials). Within each reversal episode we 
included either 1 or 2 PE (probabilistic error) trials, in 
which “wrong”-feedback was given for correct choices, 
even though the reward contingencies had not changed. 
At the start of each choice trial, participants were pre-
sented with a response cue consisting of 2 white frames 
surrounding the colors and prompting the participants to 
press the left or right button on a response box to choose 
one color. Response feedback (choice outcome) was given 
subsequently using a centrally presented white “smiley” 
(correct choice) or red “frowny” (incorrect choice) face 
and an earnings counter changing incrementally by ±1p. 
In trials following reversal or PE events, ie, in those tri-
als used for fMRI analysis, response cues and feedback 
stimuli were presented with a jittered duration (cue: 4–8 s, 
mean 5.5 s; feedback: 0.75 s followed by 3–7 s [mean 4.5 
s] inter-trial-interval [ITI]: paradigm schematic in supple-
mentary figure S2). To reduce scanning time, in all other 
(standard) trials we used fixed and shorter stimulus dura-
tions (cue: 2 s, feedback: 0.75 s). ITIs showed the 2 col-
ors without response cue or feedback and were 0.5 s long 
after standard trials and between 4 and 8 s (mean 5.5 s) 
after PEs and reversals. BOLD response analysis focused 
on brain activation differences as a function choice 
behavior (switch > stay response) or choice outcomes 
(reward > punishment) in post-PE and postreversal tri-
als. We selected those trials for analysis as they yielded a 
comparatively balanced number of rewards/and punish-
ments (correct/vs incorrect choices) compared to stand-
ard trials (which were disproportionally more rewarded 
than punished. These regressors were modeled BOLD 
during decisional processes under high levels of uncer-
tainty, ie, after participants had to choose a stay or switch 
strategy in response to an unexpected punishment in the 
previous (PE or reversal) trial and during rewarding or 
punishment based feedback. BOLD signal changes were 
regressed by task predictor functions (switch > stay and 
reward > punishment) convolved with a canonical hemo-
dynamic response function. For the switch-stay contrast, 
predictor functions were synchronized with the onset of 
the response cue in post-PE/-reversal trials; having a dura-
tion of 4000  ms and including both predecisional and 
response processing. For the reward-punishment contrast 
and predictor time courses were locked to the onset of 
feedback stimuli in post-PE and postreversal trials, with 
a fixed duration of 3750 ms, which corresponded to the 
earliest possible start of the next choice trial. For each 
subject, statistical contrast images reward > punishment 
and switch > stay were obtained, which have previously 
shown good test–retest reliability.46 Group level analysis 
was carried out using FLAME (FMRIB’s Local Analysis 
of Mixed Effects).47 We explored the (1) group level con-
trasts (1-sample t-tests) and (2) SCZ-RPS group effects 
(2-sample t-tests) across (a) the whole brain, (b) within 
the ventral striatum (VS) region of interest, defined as the 
bilateral accumbens in the Harvard-Oxford Subcortical 
Structural Atlas, based on our previous observations 
between VS BOLD and SCZ-RPS,14,34 and (c) a prein-
vestigated reward network.14 For whole group analysis 
(1-sample t-tests) the family wise error (FWE) was con-
trolled by estimating the minimum Z intensity using fsl’s 
“ptoz” function and contrast smoothness parameters, 
where Z > 4.2 controlled for the FWE across both choice 
decision and outcome. For between SCZ-RPS group com-
parisons, the family-wise error rate was controlled with 
nonparametric permutation testing (5000 permutations) 
and threshold free cluster enhancement (TFCE) which 
effectively controls for multiple comparisons, compared 
to cluster extent thresholding.48 The SCZ-RPS 2-sample 
t-tests for the switch > stay and reward > punishment 
contrast images, were adjusted for confounds (sex, rela-
tive, and mean frame wise displacement).
Results
Participant Stratification by SCZ-RPS
We successfully phenotyped 197 individuals—99 (52 
female, 47 male) individuals with low SCZ-RPS and 98 
individuals (52 female, 46 male) with high SCZ-RPS 
from either tail of the SCZ-RPS distribution from a 
large, genotyped population (figure  1). There were also 
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evidence of violation from homoscedasticity between the 
SCZ-RPS groups, where the cluster was more diffuse for 
the high SCZ-RPS compared to the low SCZ-RPS group 
(Levene’s test: F1,195 = 16.1, P < .001).
Psychopathology and Cognition
For individuals where SCZ-RPS and psychotic expe-
riences data were available (n  =  172), we observed a 
nominal association between an increased incidence of 
psychotic experiences and high SCZ-RPS group alloca-
tion (psychotic experiences in low [N = 5; 5.75%] and high 
[N = 12; 17.65%] SCZ-RPS, P =  .039). For individuals 
where SCZ-RPS and WISC-III measures were available 
(n = 183), we observed no association between SCZ-RPS 
and any IQ dimension (table 1).
Structural Neuroimaging
We observed no association between SCZ-RPS group and 
ICV, average thickness or total surface area (P > .1 in all 
cases). We observed nominal associations (PUNCORRECTED 
< .05) between SCZ-RPS and cortical thickness in the 
superior parietal cortex and precuneus and between 
SCZ-RPS and surface area the caudal middle frontal 
gyrus (supplementary figures S3a and S3b), although 
these did not withstand correction for multiple compari-
sons. Regression analysis of the subcortical ROIs showed 
no association between the SCZ-RPS and subcortical 
volumes (supplementary figure S3c).
Functional Neuroimaging
The combined group effects (1-sample t-tests) across all 
participants (for switch > stay and reward > punishment) 
produced similar z-maps as previously observed.14,49 
Choice decisions (switch > stay) Z-maps were associated 
with BOLD signal increases in the bilateral precentral, 
postcentral, and superior parietal gyri. Choice outcomes 
(reward > punishment) z-maps was associated with a 
wide cortico-limbic network including superior frontal 
cortex, precentral gyrus, cingulate cortices, and hippo-
campal-amygdala complex (figures  2a and 2b, respec-
tively). After correcting for FWE using TFCE correction 
(PCORRECTED < .05), we found no effect of SCZ-RPS group 
in the choice decision contrast. However, we identified 
SCZ-RPS related group differences in the choice out-
come contrast (reward > punishment) across the whole 
brain (PCORRECTED  =  .013), VS-ROI (PCORRECTED  =  .037) 
and reward-related ROIs (PCORRECTED = .008), controlling 
for confounds (figures 2c–e, respectively), where the high 
SCZ-RPS showed higher BOLD than the low SCZ-RPS 
in both cases. The low and high SCZ-RPS groups were 
matched for performance (accuracy [% correct] and/reac-
tion time) in the post-PE and postreversal trials where 
choice decision and outcome where modeled (supplemen-
tary table S1, and supplementary figure S4).
Brain–Behavior Relationships
We then investigated whether the SCZ-RPS–related var-
iation in BOLD (figures 2c–e) was related to the SCZ-
RPS–related variation in psychotic experiences that we 
observed. In a series of  linear regression models, we 
found no evidence for association between SCZ-RPS 
related BOLD in any of  the clusters identified within 
the whole brain or ROI analysis (P > .1, in all cases). 
We further averaged performance across postprobabi-
listic error and postreversal trials and found no rela-
tionship BOLD in any SCZ-RPS related brain regions 
(P > .1, in all cases).
Discussion
We first outline an RbG strategy for the deep phenotypic 
characterization of healthy, young individuals with either 
a low or high burden of common risk alleles for SCZ, 
as estimated via SCZ-RPS. There was more variation in 
SCZ-RPS in the high SCZ-RPS group, due to difficultly 
in participant recruitment in this SCZ-RPS group, con-
sistent with the previous observation that higher SCZ-
RPS is associated with a higher incidence of participation 
attrition/nonparticipation.37 Our finding of a nominal 
association between SCZ-RPS and psychotic experi-
ence are similar to a recent observation (supplementary 
eTable 3 in Jones et al8). It is currently unknown whether 
SCZ-RPS reflects a specific risk to develop psychotic 
symptoms or relates to broader psychopathological con-
structs such as common mental distress.50,51 Recent work 
aimed to uncover the relationship between SCZ-RPS and 
specific facets of SCZ psychopathology,8 however this 
work is ongoing.52 The lack of replication of the associa-
tion between SCZ-RPS and IQ may have been observed 
as our study was not powered to find effects of the size 
previously reported.5
We also provide an analysis of putative structural brain 
differences (volume, thickness and surface area) between 
Table 1. OR and β Coefficients (±95% Confidence Intervals) for 
Psychotic Experiences and WISC-III IQ Measures by SCZ-RPS 
Group (Higher OR/Coefficients Reflect an Association With the 
High SCZ-RPS Group)
Phenotype Estimate Lower 0.95% Upper 0.95% P
Psychotic experiences 1.100a 1.00660 1.20283 .039
WISC-III  
(verbal)
0.217b −4.48233 4.91643 .927
WISC-III  
(performance)
1.944b −2.83438 6.72296 .423
WISC-III  
(total)
1.606b −2.77053 5.98341 .470
aOdds ratio (OR).
bβ coefficients.
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the SCZ-RPS groups. We found no effect of SCZ-RPS 
on whole brain measures (ICV, cortical thickness or 
total cortical surface area), which is likely to rule out any 
shared variance at the level (R2 > .03) for which our study 
was powered. While we observed no relationship between 
SCZ-RPS and brain morphometry (in concordance 
with other SCZ polygenic imaging studies13,32,33,53), sev-
eral studies suggest that associations between SCZ-RPS 
and brain structure may be region specific54 or interact 
with other risk factors,7,55,56 which remain relatively unex-
plored. In our sample, there were nominally significant 
differences between groups for cortical thickness and sur-
face area in parietal and frontal brain regions; however 
these observations should be confirmed in independent 
studies before we can assess their role in the etiology of 
genetic risk for SCZ.
Critically, we observed an impact on SCZ-RPS on 
BOLD during reversal learning, while performance 
remained intact. SCZ-RPS was related to increased 
BOLD in the (1) VS, (2) extended reward-related search 
space, and (3) across a broader cortical network—extend-
ing into posterior regions of the brain. While there are 
similarities between these observations (eg, increased 
VS-BOLD and SCZ-RPS during reward receipt34), we 
observed several differences between the current find-
ings and our previous findings. Specifically, we observed 
altered BOLD signal during the processes of choice out-
come (ie, during reward receipt), compared to our pre-
vious observation linking SCZ-RPS to BOLD during 
choice decision (ie, uncertainty of outcome). However, 
we suggest that these observations largely conform to 
our broader hypothesis that BOLD signal in the reward 
processing network is associated with SCZ-RPS.14,34 We 
expand upon our previous findings by demonstrating 
that the altered BOLD signal associated with increased 
SCZ-RPS extends across a wider network including the 
hippocampal, cingulate cortex, precuenus, and thalamus. 
Imaging studies of individuals with increased genetic risk 
for SCZ have also implicated these cortical/subcortical 
regions,57,58 which may reflect the recruitment of alter-
native/additional neural resources proposed for other 
SCZ-associated fMRI-based endophenotypes.59 In line 
with previous hypotheses,18,19 these observations suggest 
that the common genetic architecture of SCZ may man-
ifest via alterations in the activity of cognitive-motiva-
tional brain networks (eg, supporting reversal learning), 
in the presence of a relatively intact cortical/subcorti-
cal morphometry. This hypothesis is also supported by 
studies showing common genetic overlap between SCZ 
and cognition,5,11 but not brain volumes.13 Although we 
find evidence supporting SCZ-RPS related alterations in 
VS-BOLD in healthy individuals, it remains unknown 
how these alterations predispose risk to SCZ. Studies 
suggest that SCZ-related alterations in VS-BOLD could 
relate several symptom dimensions including (1) myopic 
decision making (similar to the VS-BOLD alterations 
observed in ADHD)60–62; (2) positive symptoms (such as 
delusions/aberrant salience)63–66 or (3) negative/depressive 
symptoms (such as anhedonia/avolition).24,67–69
Our future objectives are to explore the SCZ-RPS 
group differences across a range of neurophysiologi-
cal and connectivity measures. We anticipate that these 
analyses will further elucidate the brain systems that are 
linked to the common genetic architecture of SCZ. In a 
secondary analysis, we hope to further establish specific 
SCZ biological pathways (such as glutamate receptor 
Fig. 1. Characterization of the schizophrenia polygenic risk group in the neuroimaging sample (calculated by SCZ-RPS—left; defined by 
rank—right; N = 197; low = 99, high = 98) compared to the entire genotyped cohort (N = 8169, not including the neuroimaging sample).
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complexes, voltage-gated calcium channels, FMRP bind-
ing proteins3) that may preferentially influence these 
putative associations. By identifying specific neural 
antecedents, we aim to provide novel biological insight 
into brain systems (and associated psychopathological 
symptoms) disrupted in SCZ.
Fig. 2. One-sample t-tests for (a) choice decision (switch > stay) and (b) choice outcome (reward > punishment). Both 1-sample t-tests are 
corrected for the family wise error across the whole brain (Z > 4.2). Z-map intensity is denoted by the colorbar for a and b. For the SCZ-RPS 
2-sample t-tests, all significant voxels (non-white, within brain or region of interest boundaries) are corrected for the family wise error (PFWE-
CORRECTED < 0.05) across the (c) whole brain, (d) ventral striatum (VS), and (e) related-related region of interests (ROIs) adopted from Lancaster 
et al,14 all using threshold free cluster enhancement.
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In conclusion, we provide a framework by which to 
explore the impact of RPS on quantitative neural and 
behavioral traits. This approach offers the statistical 
power of a large genotyped population study, without 
the cost of extensive phenotypic characterization. This 
method could also be used in other systems-biology 
approaches such as the neuronal conversion and phe-
notypic characterization of low/high SCZ-RPS human 
fibroblasts, classify the efficacy of response in clinical tri-
als and psychological intervention programs.
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Supplementary data are available at Schizophrenia 
Bulletin online.
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